Structure of the DDB1-CRBN E3 Ubiquitin Ligase in Complex with Thalidomide

Total Page:16

File Type:pdf, Size:1020Kb

Structure of the DDB1-CRBN E3 Ubiquitin Ligase in Complex with Thalidomide Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Fischer, E. S., K. Böhm, J. R. Lydeard, H. Yang, M. B. Stadler, S. Cavadini, J. Nagel, et al. 2015. “Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.” Nature 512 (7512): 49-53. doi:10.1038/nature13527. http://dx.doi.org/10.1038/ nature13527. Published Version doi:10.1038/nature13527 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:16121077 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA HHS Public Access Author manuscript Author Manuscript Author ManuscriptNature. Author ManuscriptAuthor manuscript; Author Manuscript available in PMC 2015 May 07. Published in final edited form as: Nature. 2014 August 7; 512(7512): 49–53. doi:10.1038/nature13527. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide Eric S. Fischer1,2, Kerstin Böhm1,2, John R. Lydeard3, Haidi Yang5, Michael B. Stadler1,2,6, Simone Cavadini1,2, Jane Nagel5, Fabrizio Serluca5, Vincent Acker4, Gondichatnahalli M. Lingaraju1,2, Ritesh B. Tichkule5, Michael Schebesta5, William C. Forrester5, Markus Schirle5, Ulrich Hassiepen4, Johannes Ottl4, Marc Hild5, Rohan E. J. Beckwith5, J. Wade Harper3, Jeremy L. Jenkins5, and Nicolas H. Thomä1,2,* 1Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH-4058 Basel, Switzerland 2University of Basel, Petersplatz 10, CH-4003 Basel, Switzerland 3Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston MA 02115, USA 4Novartis Pharma AG, Institutes for Biomedical Research, Novartis Campus, CH-4056 Basel, Switzerland 5Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge MA 02139, USA 6Swiss Institute of Bioinformatics, Maulbeerstrasse 66, CH-4058 Basel, Switzerland Abstract In the 1950s the drug thalidomide administered as a sedative to pregnant women led to the birth of thousands of children with multiple defects. Despite its teratogenicity, thalidomide and its derivatives lenalidomide and pomalidomide (together known as Immunomodulatory Drugs: IMiDs) recently emerged as effective treatments for multiple myeloma and 5q-dysplasia. IMiDs target the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and promote the ubiquitination of Ikaros/Aiolos transcription factors by CRL4CRBN. Here we present the crystal structure of the DDB1-CRBN complex bound to thalidomide, lenalidomide and pomalidomide. The structure establishes CRBN as a CRL4CRBN substrate receptor, which enantioselectively binds IMiDs. Through an unbiased screen we identify the homeobox transcription factor MEIS2 as an endogenous substrate of CRL4CRBN. Our studies suggest that IMiDs block endogenous substrates (MEIS2) from binding to CRL4CRBN when recruiting Ikaros/Aiolos for degradation. *Correspondence and requests for materials should be addressed to [email protected]. Supplementary information is linked to the online version of the paper at www.nature.com/nature. Author Contributions E.S.F., N.H.T., J.L.J and W.C.F initiated the project. E.S.F. and K.B. conducted the protein purification and crystallisation. S.C. pre-screened protein complexes by EM. E.S.F collected data, processed and refined x-ray data. E.S.F. and N.H.T. analysed the structures. E.S.F. performed in vitro experiments and, with the help of U.H., developed and performed TR-FRET and FP assays. E.S.F. performed protein array experiments, M.B.S. and E.S.F. analysed the data. E.S.F., K.B., J.R.L., H.Y., M.H., J.W.H. and N.H.T. conceived and performed the cell biological characterisation. R.B.T. and R.E.J.B. conceived and conducted chemical syntheses. J.N. and M.S. performed proteomics. V.A. and J.O. did the DSF experiments. F.S. and M.S. did the zebrafish experiments. E.S.F. and N.H.T. wrote the manuscript. All authors assisted in editing the manuscript. Author Information The following structural coordinates have been reported and were submitted to the Protein Data Bank under accession numbers: hsDDB1-ggCRBN-thalidomide (pdb:4CI1), hsDDB1-ggCRBN-lenalidomide (pdb:4CI2), hsDDB1-ggCRBN- pomalidomide (pdb:4CI3). Human protein microarray data sets generated for this study are available from GEO (http:// www.ncbi.nlm.nih.gov/geo) under accession GSE57554. Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests. Fischer et al. Page 2 This dual activity implies that small molecules can principally modulate a ligase to up- or down- Author Manuscript Author Manuscript Author Manuscript Author Manuscript regulate the ubiquitination of proteins. Thalidomide (α-(N-phthalimido)glutarimide) was introduced to the market in 1954 by Chemie Grünenthal. Initially promoted as a sedative with anti-emetic properties1,2, it became popular in the treatment of ‘morning sickness’3. In 1961, thalidomide taken in the first trimester of pregnancy was implicated in frequent limb deformities in infants4,5. Between 8,000 and 12,000 affected children were born before the drug was banned. Interest in thalidomide revived in 1965 when it was shown to have immunomodulatory and anti- inflammatory properties in erythema nodosum leprosum (ENL), an inflammatory complication of leprosy6. In 1994, thalidomide was found to inhibit fibroblast growth factor (bFGF)-induced formation of new blood vessels7. These findings prompted clinical trials exploring thalidomide use in anti-angiogenic cancer therapy. The efficacy of thalidomide and its derivatives lenalidomide and pomalidomide (collectively known as IMiDs) has since been demonstrated in several blood cancers8 : newly diagnosed multiple myeloma (thalidomide)9, refractory multiple myeloma (lenalidomide/pomalidomide) and 5q-deletion- associated myelodysplastic syndrome (lenalidomide). The target of thalidomide, cereblon (CRBN), is a ubiquitously expressed protein that is part of the cullin-4 E3 ubiquitin ligase complex, CUL4-RBX1-DDB1 (CRL4)10. Mutations in CRBN are associated with autosomal recessive non-syndromic mental retardation (MR)11. In myeloma cells, the anti-proliferative activities of IMiDs are linked to CRBN expression12,13, making IMiDs the first clinically approved E3 ubiquitin ligase inhibitors with specificity for the CRL4CRBN ligase12. The IMiD anti-proliferative and immunomodulatory effects have recently been linked to drug-induced ubiquitination and degradation of Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors by CRL4CRBN14 –16. Accordingly, loss of CRBN is a common determinant of drug resistance in myeloma cells12. How IMiD binding affects the CRL4CRBN ligase at the molecular level remains unclear. We set out to examine the role of CRBN within the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3-ligase complex, characterising the effect of IMiD binding on ligase activity. Structure of DDB1-CRBN bound to IMiDs We crystallized a chimeric complex of human DDB1 (DDB1) and chicken CRBN (ggCRBN) bound to thalidomide (refined to 3.0 Å), lenalidomide (3.0 Å) and pomalidomide (3.5 Å) (Fig. 1a, b and Extended Data Table 1). The high level of sequence conservation between human and chicken CRBN (Extended Data Fig. 1a, b) allows structural insights to be inferred directly from chicken to human CRBN. All subsequent biochemical and cell- biological experiments were performed with human full-length proteins. ggCRBN consists of three sub-domains (Extended Data Fig. 2a–f): a seven-stranded β-sheet located in the N- terminal domain (NTD, residues 1–185) (Extended Data Fig. 2a), a 7-α-helical bundle domain (HBD, residues 186–317) involved in DDB1 binding (Fig. 1c), and a C-terminal domain composed of 8 β-sheets (CTD, residues 318–445) (Fig. 1b). DDB1 comprises three seven-bladed WD40 β-propellers arranged in a triangular fashion (BPA, BPB and BPC)17 with ggCRBN attaching to a cavity between the BPA and BPC propellers (Fig. 1c). The molecular basis of the HBD-mediated attachment of ggCRBN to DDB1 defines a novel Nature. Author manuscript; available in PMC 2015 May 07. Fischer et al. Page 3 class of DDB1 binders and differs in detail from previous DDB1 attachment modules17 –20 Author Manuscript Author Manuscript Author Manuscript Author Manuscript (Extended Data Fig. 2e, f). The ggCRBN N-terminal region (residues 46–317) including the NTD and HBD resembles the N-terminal domain of bacterial Lon proteases (PDB: 3LJC - RMSD of 2.7 Å over 178 residues aligned) (Extended Data Fig. 2b). The CTD harbours the thalidomide-binding pocket and contains a conserved Zn2+-binding site situated approximately 18 Å from the compound (Fig. 1a, b). The Zn2+ ion is coordinated through conserved cysteine residues 325, 328, 393 and 396. The ggCRBN-CTD shares structural similarity with the pseudouridine synthase and archaeosine transglycosylase (PUA) fold family21 involved in the binding of diverse sets of ligands (Extended Data Fig. 2c, d). IMiD binding to CRBN Thalidomide, lenalidomide and pomalidomide (Fig. 2a–c and Extended Data Fig. 3a–i) bind a pocket on the ggCRBN-CTD (Fig. 1b) situated in a surface groove that is highly conserved across CRBN orthologues (Extended Data Fig. 1b). The three ligands superimpose with very little deviation in the α-(isoindolinone-2-yl) glutarimide moiety, which contributes the majority of interactions between the receptor and the compounds and represents the main pharmacophore22. The glutarimide group is held in a buried cavity between ggCRBN sheets β10 and β13(Fig. 2d). Glutarimide carbonyls (C2, C6) and the intervening amide (N1) are in hydrogen-bonding distance to ggCRBN residues His380 and Trp382, respectively (Fig. 2c, d). A delocalised lone pair connects the glutarimide nitrogen with the two glutarimide carbonyls (C2-N1-C6) and is coplanar with Trp382. The opposing aliphatic face of the glutarimide ring (C3, C4 and C5) is in tight Van-der-Waals contact with a hydrophobic pocket lined by Trp382, Trp388, Trp402 and Phe404.
Recommended publications
  • P63 Is a Cereblon Substrate Involved in Thalidomide Teratogenicity
    ARTICLES https://doi.org/10.1038/s41589-019-0366-7 p63 is a cereblon substrate involved in thalidomide teratogenicity Tomoko Asatsuma-Okumura 1,5, Hideki Ando1,5, Marco De Simone2, Junichi Yamamoto1, Tomomi Sato1, Nobuyuki Shimizu1, Kazuhide Asakawa1, Yuki Yamaguchi3, Takumi Ito1,4, Luisa Guerrini2* and Hiroshi Handa 1* Cereblon (CRBN) is a primary target of thalidomide and mediates its multiple pharmacological activities, including teratogenic and antimyeloma activities. CRBN functions as a substrate receptor of the E3 ubiquitin ligase CRL4, whose substrate specificity is modulated by thalidomide and its analogs. Although a number of CRL4CRBN substrates have recently been identified, the sub- strate involved in thalidomide teratogenicity is unclear. Here we show that p63 isoforms are thalidomide-dependent CRL4CRBN neosubstrates that are responsible, at least in part, for its teratogenic effects. The p53 family member p63 is associated with multiple developmental processes. ∆Np63α is essential for limb development, while TAp63α is important for cochlea develop- ment and hearing. Using a zebrafish model, we demonstrate that thalidomide exerts its teratogenic effects on pectoral fins and otic vesicles by inducing the degradation of ∆Np63α and TAp63α, respectively. These results may contribute to the invention of new thalidomide analogs lacking teratogenic activity. halidomide was originally used to relieve morning sick- serve as molecular glues between the enzyme and the substrates8–14. ness and caused serious congenital birth defects in
    [Show full text]
  • The Consortium of Swiss Academic Libraries the Consortium of Swiss Academic Libraries
    Research Collection Other Conference Item Times change and we change with them: the Consortium of Swiss Academic Libraries the Consortium of Swiss Academic Libraries Author(s): Boutsiouci, Pascalia Publication Date: 2015 Permanent Link: https://doi.org/10.3929/ethz-a-010439524 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library TIMES CHANGE AND WE CHANGE WITH THEM The Consortium of Swiss Academic Libraries ICoASL – 4th International Conference of Asian Special Libraries 2015 Pascalia Boutsiouci, Seoul, April 23 of 2015 AGENDA 1 Overview Switzerland and Higher Education 2 Overview Consortium of Swiss Academic Libraries 3 Our business – range of activity 4 Cooperation with our partner libraries 5 projects © Consortium of Swiss Academic Libraries | 2015 2 Overview Switzerland 1 and Higher Education © Consortium of Swiss Academic Libraries | 2015 3 THE LANDSCAPE Switzerland lies in the heart of Europe 8.2 million people 26 cantons Four official languages Matterhorn, Zermatt (4,478 m/14,692 ft) / Image source: http://www.zermatt.ch/Media/Pressecorner/Fotodatenbank/Matterhorn/Sicht-aufs- . German (66%) Matterhorn-vom-Gornergrat . French (23%) . Italian (9%) . Rheto- Romanic (1%) Image source: http://en.wikipedia.org/wiki/Switzerland#/media/File:Europe-Switzerland.svg © Consortium of Swiss Academic Libraries | 2015 4 SWITZERLAND = CONFOEDERATIO HELVETICA = CH Federal parliamentary republic consisting of 26 cantons wth Bern as the seat of the federal authorities Germany France Liechtenstein Austria Italy Image source:http://de.wikipedia.org/wiki/Datei:Switzerland,_administrative_divisions_-_de_-_colored.svg © Consortium of Swiss Academic Libraries | 2015 5 HIGHER EDUCATION IN SWITZERLAND Official Higher Education Institutions 10 Cantonal Universities .
    [Show full text]
  • DDB1 Targets Chk1 to the Cul4 E3 Ligase Complex in Normal Cycling Cells and in Cells Experiencing Replication Stress
    Published OnlineFirst March 10, 2009; DOI: 10.1158/0008-5472.CAN-08-3382 Research Article DDB1 Targets Chk1 to the Cul4 E3 Ligase Complex in Normal Cycling Cells and in Cells Experiencing Replication Stress Van Leung-Pineda,1 Jiwon Huh,1 and Helen Piwnica-Worms1,2,3 Departments of 1Cell Biology and Physiology and 2Internal Medicine and 3Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri Abstract protein FANCE (8, 10–12). Chk1 carries out its functions both in the The Chk1 protein kinase preserves genome integrity in normal nucleus and at the centrosome (13). Drugs that block Chk1 kinase proliferating cells and in cells experiencing replicative and activity or enhance its proteolysis by interfering with binding to genotoxic stress. Chk1 is currently being targeted in antican- heat shock protein 90 (HSP90) are currently being tested as cer regimens. Here, we identify damaged DNA-binding protein anticancer agents (14–17). 1 (DDB1) as a novel Chk1-interacting protein. DDB1 is part of Chk1 is regulated by reversible phosphorylation and by an E3 ligase complex that includes the cullin proteins Cul4A ubiquitin-mediated proteolysis. Under periods of replicative stress, and Cul4B. We report that Cul4A/DDB1 negatively regulates the ATRIP/ATR module binds to single-stranded DNA and, Chk1 stability in vivo. Chk1 associates with Cul4A/DDB1 together with Rad17 and the 9-1-1 complex, activates Chk1 in a Claspin-dependent manner (18–22). ATR directly phosphorylates during an unperturbed cell division cycle and both Chk1 317 345 phosphorylation and replication stress enhanced these inter- Chk1 on two COOH-terminal residues: Ser (S317) and Ser actions.
    [Show full text]
  • Treating Cancer with Proton Therapy Information for Patients and Family Members Professor Dr
    Treating Cancer with Proton Therapy Information for patients and family members Professor Dr. med. Damien Charles Weber, Dear readers Head and Chairman, Proton therapy is a special kind of radiation therapy. For many years now, patients Centre for Proton Therapy suffering from certain tumour diseases have successfully undergone proton radi- ation therapy at the Paul Scherrer Institute’s Centre for Proton Therapy. This brochure is intended to give a more detailed explanation of how proton ther- apy works and provide practical information on the treatment we offer at our facil- ity. We will include a step-by-step description of the way in which we treat deep- seated tumours. We will not deal with the treatment of eye tumours in this brochure. If you have further questions on the proton therapy carried out at the Paul Scherrer Institute, please do not hesitate to address these by getting in touch with our secretaries. Contact details are provided at the end of the brochure. 2 Contents 4 Radiation against cancer 10 Physics in the service of medicine 14 Four questions for Professor Dr. Tony Lomax, Chief Medical Physicist 16 Practical information on treatment at PSI 20 Four questions for Dr. Marc Walser, Senior Radiation Oncologist 22 In good hands during treatment 28 Four questions for Lydia Lederer, Chief Radiation Therapist 30 Treating infants and children 36 Children ask a specialist about radiation 38 PSI in brief Radiation against cancer 4 Because it can be used with great ac- The most important cancer therapies curacy, proton therapy is a particularly are: sparing form of radiation treatment • surgery (operation), with lower side effects.
    [Show full text]
  • Annual Report 2018 Swiss Nanoscience Institute University of Basel
    EINE INITIATIVE DER UNIVERSITÄT BASEL UND DES KANTONS AARGAU Annual Report 2018 Swiss Nanoscience Institute University of Basel Swiss Nanoscience Institute University of Basel Klingelbergstrasse 82 4056 Basel Switzerland www.nanoscience.ch The Swiss Nanoscience Institute (SNI) is a research initiative of the Canton of Aargau and the University of Basel. Swiss Nanoscience Institute Klingelbergstrasse 82 4056 Basel Switzerland www.nanoscience.ch Cover: Atomic force microscopic image of “nano-bone” molecules on a gold surface. The molecule is a buil- ding block for the formation of two-dimensional organic topological insulators (Rémy Pawlak, Department of Physics, University of Basel). © Swiss Nanoscience Institute, March 2019 Content 3 Foreword 4 Swiss Nanoscience Institute — The interdisciplinary center of excellence for nanosciences in Northwestern Switzerland 6 Network 8 News from the network 14 The Paul Scherrer Institute – 30 years old and a key partner on the SNI network 16 Nano Study Program 18 Glued wounds heal better – Tino Matter wins the prize for the best master’s thesis 20 Discussing science at SmallTalk – Students organize their own symposium about the block courses 22 PhD School 24 SNI PhD School – An excellent start of a scientific career 29 Multiple awards – Daniel Riedel wins several prizes 30 SNI Professors 32 Martino Poggio studies nanowires – These tiny wires with special properties have a variety of potential applications 34 Roderick Lim researches the transport processes and mechanical properties of cells – Promising
    [Show full text]
  • Cereblon and Its Downstream Substrates As Molecular Targets of Immunomodulatory Drugs
    Int J Hematol (2016) 104:293–299 DOI 10.1007/s12185-016-2073-4 PROGRESS IN HEMATOLOGY Mechanisms of action of novel drugs in multiple myeloma and those responsible for the acquired resistance Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs Takumi Ito1,2 · Hiroshi Handa1 Received: 15 June 2016 / Revised: 19 July 2016 / Accepted: 19 July 2016 / Published online: 26 July 2016 © The Japanese Society of Hematology 2016 Abstract Thalidomide was first developed as a sedative History of immunomodulatory drugs (IMiDs) around 60 years ago, but exhibited teratogenicity, leading to serious defects such as limb deformities. Nevertheless, Immunomodulatory drugs (IMiDs) are a new class of anti- thalidomide is now recognized as a therapeutic drug for the cancer drugs for which the parent molecule is thalidomide. treatment of Hansen’s disease and myeloma. Immunomod- Thalidomide (Fig. 1) was developed as a sedative in 1950s ulatory drugs (IMiDs), a new class of anti-cancer drug by the German pharmaceutical company Grunenthal. derived from thalidomide, have also been developed and Experiments using rodents initially suggested it to be safe exert potent anti-cancer effects. Although the molecular for use in humans, and the drug was sold over 40 countries, mechanism of thalidomide and IMiDs remained unclear for including Japan. However, as is widely known, thalidomide a long time, cereblon, a substrate receptor of the CRL4 E3 was found to have serious teratogenic effects. Use during ubiquitin ligase was identified as a primary direct target by pregnancy is associated with developmental defects of the a new affinity technique. A growing body of evidence sug- limbs and ears.
    [Show full text]
  • Particle Accelerator Activities at the Paul Scherrer Institut
    PSI Bericht Nr. 17-07 December 2017 Particle Accelerator Activities at the Paul Scherrer Institut Terence GARVEY Paul Scherrer Institut, Villigen, Switzerland 5232 Division of Large Research Infrastructures Invited paper presented at Les Journées Accélérateurs de la Société Française de Physique, Roscoff, 3rd – 6th October, 2017. Resumé Les Activités Accélérateur à l’Institut Paul Scherrer. L'Institut Paul Scherrer exploite deux complexes d'accélérateurs en tant que ‘centre- serveurs’ pour une grande communauté de chercheurs. Il s'agit de l'Accélérateur de Protons à Haute Intensité (HIPA) et de la Source de Lumière Suisse (SLS). HIPA est un cyclotron à protons de 590 MeV. Il sert à produire des neutrons par spallation pour la recherche en physique de la matière condensée et à produire des muons et d'autres particules secondaires pour la recherche en magnétisme et en physique des particules. Le SLS est un anneau de stockage d’électrons de 2,4 GeV utilisé comme source de rayonnement synchrotron de 3ème génération fournissant des photons pour une large gamme de disciplines scientifiques. En plus de ces deux installations, l'Institut met progressivement en service un laser à électrons libres en rayons X (SwissFEL) qui fournira aux chercheurs des impulsions femto-seconde intenses à partir d’une ligne de rayons X ‘dur’ (ARAMIS) et de rayons X ‘mou’ (ATHOS). L'Institut exploite également un cyclotron supraconductrice à 250 MeV (COMET) aux fins de la thérapie par proton. Le centre de thérapie a récemment été équipé d'un troisième « gantry » rotatif qui est en cours de mise en service. Un « upgrade » du système de radiofréquence de HIPA et des projets pour "SLS-2" seront présentés.
    [Show full text]
  • The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis
    Hindawi BioMed Research International Volume 2018, Article ID 9651320, 10 pages https://doi.org/10.1155/2018/9651320 Research Article The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis Jingwei Liu, Hao Li, Liping Sun, Xue Feng, Zhenning Wang , Yuan Yuan , and Chengzhong Xing Tumor Etiology and Screening Department, Cancer Institute and General Surgery, Te First Hospital of China Medical University and Key Laboratory of Cancer Etiology and Prevention, Liaoning Provincial Education Department, China Medical University, Shenyang 110001, China Correspondence should be addressed to Yuan Yuan; [email protected] and Chengzhong Xing; [email protected] Received 19 October 2017; Revised 12 December 2017; Accepted 14 December 2017; Published 15 January 2018 Academic Editor: Paul W. Doetsch Copyright © 2018 Jingwei Liu et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Nucleotide excision repair (NER) plays a critical role in maintaining genome integrity. Tis study aimed to investigate theexpressionofNERgenesandtheirassociationswithcolorectalcancer(CRC)development.Method. Expressions of NER genes in CRC and normal tissues were analysed by ONCOMINE. Te Cancer Genome Atlas (TCGA) data were downloaded to explore relationship of NER expression with clinicopathological parameters and survival of CRC. Results. ERCC1, ERCC2, ERCC5, and DDB2 were upregulated while ERCC4 was downregulated in CRC. For colon cancer, high ERCC3 expression was related to better T stage; ERCC5 expression indicated deeper T stage and distant metastasis; DDB2 expression suggested earlier TNM stage. For rectal cancer, ERCC2 expression correlated with favourable T stage; XPA expression predicted worse TNM stage.
    [Show full text]
  • (UV-DDB) Dimerization and Its Roles in Chromatinized DNA Repair
    Damaged DNA induced UV-damaged DNA-binding protein (UV-DDB) dimerization and its roles in chromatinized DNA repair Joanne I. Yeha,b,1, Arthur S. Levinec,d, Shoucheng Dua, Unmesh Chintea, Harshad Ghodkee, Hong Wangd,e, Haibin Shia, Ching L. Hsiehc,d, James F. Conwaya, Bennett Van Houtend,e, and Vesna Rapić-Otrinc,d aDepartments of Structural Biology, bBioengineering, cMicrobiology and Molecular Genetics, ePharmacology and Chemical Biology, and dUniversity of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260 AUTHOR SUMMARY Exposure to UV radiation (DDB1-CUL4A DDB2) with can damage DNA that if chromatin modification and left unrepaired can cause the subsequent steps in the mutations leading to skin repair pathway. aging and skin cancer. In Here we report the crystal humans, the nucleotide structure of the full-length excision repair (NER) * human DDB2 bound to proteins function to damaged DNA in a complex recognize and repair with human DDB1 (Fig. P1). UV-damaged DNA. Defects While a large portion of the in DNA repair caused by N-terminal region of the mutations of these repair zebrafish DDB2 in the proteins have been linked earlier structure could not to several genetic diseases, be modeled, we have characterized by cancer resolved the 3D structure of predisposition (xeroderma the N-terminal domain of pigmentosum, XP) or DDB2. Our structure reveals premature aging (Cockayne secondary interactions syndrome), illustrating the between the N-terminal Fig. P1. Composite model of a dimeric DDB1-CUL4ADDB2 ubiquitin functional significance of DDB2 domain of DDB2 and a ligase-nucleosome complex. A model of a dimeric DDB1-CUL4A in a neighboring repair proteins to genomic complex with a nucleosome core particle, generated according to the relative integrity.
    [Show full text]
  • 2018 Research Slam
    University of St.Gallen (HSG) Centro Latinoamericano-Suizo (CLS-HSG) Leading House for the Latin American Region Müller-Friedberg-Strasse 8 CH-9000 St.Gallen 2018 Research Slam Wednesday, December 19, 2018 / 10:30 to 17:10 hrs Tellstrasse 2, St.Gallen / Room 58-515 Seed Money Grants 2017 Research Merger 2018 Seed Money Grants 2018 Presentation Material of the Winning Projects The Funding Instruments SMG – Seed Money Grants 2017 + 2018 duration: 10 – 12 months grants: CHF 10’000 – CHF 25’000 applications received: 87 / projects awarded: 30 RM – Research Merger 2017 duration: 10 – 12 months grants: CHF 30’000 – CHF 50’000 applications received: 29 / projects awarded: 4 MOB – Mobility Grants 2018 duration: up to 3 months grants: up to CHF 8’000 applications received: 9 / projects awarded: 7 2018 Research Slam 2 / 22 Index Towards the detection of Earth analogues (TDEA). – SMG2017 Damien Ségransan, University of Geneva.............................................................................................................................. 5 Structural colours in natural and artificial multilayers. – SMG2017 Ullrich Steiner, University of Fribourg, Adolphe Merkle Institute .................................................................................. 5 In-operando control of nanoscale decoration of graphene and reduced graphene oxide by novel mini-reactors. – SMG2017 Ivo Utke, Empa, Eidgenössische Materialprüfungs- und Forschungsanstalt (EMPA) ................................................... 6 A dendrogeomorphic reconstruction of
    [Show full text]
  • 03 (15. Februar 2017)
    2017/03 ISSN 1661-8211 | 117. Jahrgang | 15. Februar 2017 Redaktion und Herausgeberin: Schweizerische Nationalbibliothek NB, Hallwylstrasse 15, CH-3003 Bern Erscheinungsweise: halbmonatlich, am 15. und 30. jeden Monats Hinweise unter: http://ead.nb.admin.ch/web/sb-pdf/ ISSN 1661-8211 © Schweizerische Nationalbibliothek NB, CH-3003 Bern. Alle Rechte vorbehalten Inhaltsverzeichnis - Table des matières - Sommario - Cuntegn - Table of contents Inhaltsverzeichnis - Table des matières - 220 Bibel / Bible / Bibbia / Bibla / Bible....................................... 6 Sommario - Cuntegn - Table of contents 230 Christentum, christliche Theologie / Christianisme, théologie chrétienne / Cristianesimo, teologia cristiana / Cristianissem, teologia cristiana / Christianity and Christian theology..................6 000 Allgemeine Werke, Informatik, Informationswissenschaft / Informatique, information, 290 Andere Religionen / Autres religions / Altre religioni / Autras ouvrages de référence / Informatica, scienza religiuns / Other religions............................................................... 9 dell'informazione, generalità / Informatica, infurmaziun e referenzas generalas / Computers, information and general reference........................................................................................ 1 300 Sozialwissenschaften / Sciences sociales / Scienze sociali / Scienzas socialas / Social sciences.......................... 10 000 Allgemeine Werke, Wissen, Systeme / Généralités, savoir, systèmes / Generalità, sapere, sistemi / Generalitads,
    [Show full text]
  • Chemical Ligand Space of Cereblon Iuliia Boichenko,† Kerstin Bar,̈ Silvia Deiss, Christopher Heim, Reinhard Albrecht, Andrei N
    This is an open access article published under a Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. Article Cite This: ACS Omega 2018, 3, 11163−11171 http://pubs.acs.org/journal/acsodf Chemical Ligand Space of Cereblon Iuliia Boichenko,† Kerstin Bar,̈ Silvia Deiss, Christopher Heim, Reinhard Albrecht, Andrei N. Lupas, Birte Hernandez Alvarez,* and Marcus D. Hartmann* Department of Protein Evolution, Max Planck Institute for Developmental Biology, Max-Planck-Ring 5, 72076 Tübingen, Germany *S Supporting Information ABSTRACT: The protein cereblon serves as a substrate receptor of a ubiquitin ligase complex that can be tuned toward different target proteins by cereblon-binding agents. This approach to targeted protein degradation is exploited in different clinical settings and has sparked the development of a growing number of thalidomide derivatives. Here, we probe the chemical space of cereblon binding beyond such derivatives and work out a simple set of chemical requirements, delineating the metaclass of cereblon effectors. We report co-crystal structures for a diverse set of compounds, including commonly used pharmaceuticals, but also find that already minimalistic cereblon-binding moieties might exert teratogenic effects in zebrafish. Our results may guide the design of a post-thalidomide generation of therapeutic cereblon effectors and provide a framework for the circumvention of unintended cereblon binding by negative design
    [Show full text]